| Date & Time | 3 September 2025 at 12.00-13.00 CEST |
|---|---|
| Location | Online |
Please save the date for Bridging Nordic ATMP, the new season of ATMP Webinar Series hosted by the Nordic EATRIS Nodes (Sweden, Norway and Finland). This season of the series will take place online 12.00-13.00 CEST, once a month starting 3 September 2025 with a lecture by an expert in the Advanced Therapy Medicinal Products (ATMPs) field. The next edition will feature the following speaker:
Janet Hoogstraate, PhD, Chief Executive Officer at NorthX Biologics
Talk title: ”Navigating the Translational Journey: Bridging Academia and Industry in ATMP Development”
As CEO of NorthX Biologics, Janet brings a vast amount of experience to the table. Most recently coming from a position as the managing director at Valneva, Janet has also worked in preclinical R&D at Astra Pain Control, as well as in various leadership positions in drug discovery and development in neuroscience.
She is also a trusted board member of Mireca Medicines GmbH, Alzecure Pharma AB and APL AB. Janet has a PhD in biopharmaceutical sciences from Leiden University in the Netherlands and an EMBA from Hult International School in London.
The session will be moderated by Janna Saarela, Centre Director at the Norwegian Centre for Molecular Biosciences and Medicine and National Director of EATRIS Norway.
Register for the webinar here.
Remember to save the dates and look out for updates on each webinar before the start of the event.
The next webinars will take place on:
- 1 October 2025
- 5 November 2025
- 3 December 2025
The previous events took place on:
- 5 February 2025 – Magnus Essand, Professor of Gene Therapy, Uppsala University, Chief Scientific Officer and co-founder, Elicera Therapeutics
- 12 March 2025 – David Morrow, EATRIS Senior Scientific Programme Manager
- 2 April 2025 – Seppo Ylä-Herttuala, Professor at the University of Eastern Finland
- 7 May 2025 – Kamal Mustafa, Professor at the University of Bergen
- 4 June 2025 – Marie Gårdmark, Co-founder of RegSmart Life Science AB and Anna Pasetto, Director of the Centre for Advanced Cell Therapy (ACT) at Oslo University Hospital
